Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2018 | Pages:
113 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)
The India clinical trials market size is expected to reach USD 3.15 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 8.7% over the forecast period. Globalization of clinical trials, adoption of new technology in clinical research, growing disease variation and prevalence, and increasing R&D promoting outsourcing are the key factors driving the market. India is a country of nearly 1.3 billion individuals with varying genetic background and thus offers a large treatment-naive patient pool for development of therapeutics on a range of disease conditions. Furthermore, the economic, environmental, and ecological variations in the 29 states and seven union territories in the country present the most diverse disease profiles. For instance, Rajasthan, Bihar, Jharkhand, and Uttar Pradesh have less dominance of non-communicable diseases as compared to Kerala, Tamil Nadu, and Goa. Despite this, Indian clinical trials market faced a lag phase from 2013 to 2015. This can be attributed to regulatory uncertainties. This has promoted streamlining of the regulations and has led to increasing harmonization and reduction in approval time, thus making India a favorable destination for clinical trials. Furthermore, the cost of carrying out clinical trials in India is nearly 40-70% less than that in Europe or U.S. Thus, the cost efficiency, along with availability of skilled professionals, and ease of doing business, is anticipated to fuel the market growth. The increasing R&D investments by pharmaceutical and biopharmaceutical companies have led to increased demand for Contract research Organizations (CROs) and outsourcing of trials to curb the cost. Furthermore, outsourcing enables drug companies to focus on their core competencies and aids in improving their productivity. Further key findings from the report suggest: • Phase I trials are projected to witness a remarkable CAGR of 10.5% over forecast period, attributed to increasing R&D spending by pharmaceutical and biopharmaceutical companies • Interventional study design led the market Indian clinical trials market in 2017 owing to the greater accuracy offered by them as compared to observational study design • Oncology led the indication segment in terms of market share in 2017 due to high prevalence of cancer and the consequent rise in demand for innovative therapies • Some of the key companies present in the market are IQVIA, Inc.; ICON PLC; PRA Health Sciences; GVK Biosciences; PAREXEL International Corporation; and Syngene International Ltd.
Table of Contents
Chapter 1 Report Scope
1.1 Estimates and Forecast Timeline
Chapter 2 Methodology
2.1 Research Methodology
2.1.1 Information procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
2.4 Region Share Calculation
2.5 List of Secondary Sources
2.6 List of Primary Sources
2.7 List of Abbreviations
Chapter 3 Executive Summary
3.1 Market Snapshot
Chapter 4 Industry Outlook
4.1 Market Segmentation
4.2 Business Segment Trends
4.3 Market Variable Analysis
4.3.1 Market driver analysis
4.3.1.1 Globalization of clinical trials
4.3.1.2 Adoption of new technology in clinical research
4.3.1.3 Growing disease variation and prevalence
4.3.1.4 Increasing research and development promoting outsourcing
4.3.2 Market restraint analysis
4.3.2.1 Pricing pressure
4.3.2.2 Regulatory issues.
4.4 Penetration & Growth Prospect Mapping
4.5 Business Environment Analysis tools
4.5.1 SWOT Analysis, by PEST
4.5.2 Porter's five forces analysis
4.5.3 Clinical trial registry.
4.5.4 The objective of the registry
4.5.5 Future prospects
4.5.6 Clinical trial registration process flow.
Chapter 5 Phase Estimates And Trend Analysis
5.1 Indian Clinical Trials Market: Phase Movement Analysis
5.2 Phase I
5.2.1 pHASE i market estimates and forecast, 2014 - 2025 (USD Million)
5.3 Phase II
5.3.1 PHASE II market estimates and forecast, 2014 - 2025 (USD Million)
5.4 Phase III
5.4.1 phase iii market estimates and forecast, 2014 - 2025 (USD Million)
5.5 Phase IV
5.5.1 phase iv market estimates and forecast, 2014 - 2025 (USD Million)
Chapter 6 Study Design Estimates And Trend Analysis
6.1 Indian Clinical Trials Market: Study Design Movement Analysis
6.2 Interventional trials
6.2.1 interventional trials market estimates and forecast, 2014 - 2025 (USD Million)
6.3 Observational trials
6.3.1 observational trials market estimates and forecast, 2014 - 2025 (USD Million)
6.4 Expanded access trials
6.4.1 expanded access trials market estimates and forecast, 2014 - 2025 (USD Million)
Chapter 7 Indication Estimates And Trend Analysis
7.1 Indian Clinical Trials Market: Indication Movement Analysis
7.2 Autoimmune/inflammation
7.2.1 Autoimmune/inflammation market estimates and forecast, 2014 - 2025 (USD Million)
7.2.2 Rheumatoid arthritis
7.2.3 rheumatoid arthritis market estimates and froecast, 2014 - 2025 (USD Million)
7.2.4 Multiple sclerosis
7.2.5 Multiple sclerosis market estimates and froecast, 2014 - 2025 (USD Million)
7.2.6 Osteoarthritis
7.2.7 Osteoarthritis market estimates and froecast, 2014 - 2025 (USD Million)
7.2.8 Irritable Bowel Syndrome (IBS)
7.2.9 Irritable Bowel Syndrome (IBS) market estimates and froecast, 2014 - 2025 (USD Million)
7.2.10 Others
7.2.11 others market estimates and froecast, 2014 - 2025 (USD Million)
7.3 Pain management
7.3.1 pain management market estimates and forecast, 2014 - 2025 (USD Million)
7.3.2 Chronic pain
7.3.3 Chronic pain market estimates and froecast, 2014 - 2025 (USD Million)
7.3.4 Acute pain
7.3.5 Acute pain market estimates and froecast, 2014 - 2025 (USD Million)
7.4 Oncology
7.4.1 Oncology market estimates and forecast, 2014 - 2025 (USD Million)
7.4.2 Blood cancer
7.4.3 Blood cancer market estimates and froecast, 2014 - 2025 (USD Million)
7.4.4 Solid tumors
7.4.5 Solid tumors market estimates and froecast, 2014 - 2025 (USD Million)
7.4.6 Other
7.4.7 Other market estimates and froecast, 2014 - 2025 (USD Million)
7.5 CNS Conditions
7.5.1 CNS Conditions market estimates and forecast, 2014 - 2025 (USD Million)
7.5.2 Epilepsy
7.5.3 Epilepsy market estimates and froecast, 2014 - 2025 (USD Million)
7.5.4 Parkinson's Disease (PD)
7.5.5 Parkinson's Disease market estimates and froecast, 2014 - 2025 (USD Million)
7.5.6 Huntington's Disease
7.5.7 Huntington's Disease market estimates and froecast, 2014 - 2025 (USD Million)
7.5.8 Stroke
7.5.9 Stroke market estimates and froecast, 2014 - 2025 (USD Million)
7.5.10 Traumatic Brain Injury (TBI)
7.5.11 Traumatic Brain Injury (TBI) market estimates and froecast, 2014 - 2025 (USD Million)
7.5.12 Amyotrophic Lateral Sclerosis (ALS)
7.5.13 Amyotrophic Lateral Sclerosis (ALS) market estimates and froecast, 2014 - 2025 (USD Million)
7.5.14 Muscle regeneration
7.5.15 Muscle regeneration market estimates and froecast, 2014 - 2025 (USD Million)
7.5.16 Others
7.5.17 Others market estimates and froecast, 2014 - 2025 (USD Million)
7.6 Diabetes
7.6.1 Diabetes market estimates and forecast, 2014 - 2025 (USD Million)
7.7 Obesity
7.7.1 Obesity market estimates and forecast, 2014 - 2025 (USD Million)
7.8 Cardiovascular
7.8.1 Cardiovascular market estimates and forecast, 2014 - 2025 (USD Million)
7.9 Others
7.9.1 Others market estimates and forecast, 2014 - 2025 (USD Million)
Chapter 8 Company Profiles
8.1 Strategic Framework
8.2 Company Profiles
8.2.1 IQVIA holdings Inc (QUintilesIMS)
8.2.1.1 Company Overview
8.2.1.2 Financial Performance
8.2.1.3 Product Benchmarking
8.2.1.4 Strategic Initiatives
8.2.1.5 Swot Analysis
8.2.2 Paraxel International Corporation.
8.2.2.1 Company Overview
8.2.2.2 Financial Performance
8.2.2.3 Product Benchmarking
8.2.2.4 Strategic Initiatives
8.2.2.5 Swot Analysis
8.2.3 Pharmaceutical Product Development, LLC.
8.2.3.1 Company Overview
8.2.3.2 Financial Performance
8.2.3.3 Product Benchmarking
8.2.3.4 Strategic Initiatives
8.2.3.5 Swot Analysis
8.2.4 Charles River Laboratory.
8.2.4.1 Company Overview
8.2.4.2 Financial Performance
8.2.4.3 Product Benchmarking
8.2.4.4 Strategic Initiatives
8.2.4.5 Swot Analysis
8.2.5 icon plc
8.2.5.1 Company Overview
8.2.5.2 Financial Performance
8.2.5.3 Product Benchmarking
8.2.5.4 Strategic Intiatives
8.2.5.5 Swot Analysis
8.2.6 PRA Health Sciences, INC.
8.2.6.1 Company Overview
8.2.6.2 Financial Performance
8.2.6.3 Product Benchmarking
8.2.6.4 Strategic Initiatives
8.2.6.5 Swot Analysis
8.2.7 Chiltern International Ltd (Covance Inc.).
8.2.7.1 Company Overview
8.2.7.2 Financial Performance
8.2.7.3 Product Benchmarking
8.2.7.4 Strategic Initiatives
8.2.7.5 Swot Analysis
8.2.8 Syneos Health Inc (inc research)
8.2.8.1 Company Overview
8.2.8.2 Financial Performance
8.2.8.3 Product Benchmarking
8.2.8.4 Strategic Initiatives.
8.2.8.5 Swot Analysis
8.2.9 sgs sa
8.2.9.1 Company Overview
8.2.9.2 Financial Performance
8.2.9.3 Product Benchmarking
8.2.9.4 Strategic Initiatives
8.2.9.5 Swot Analysis
8.2.10 syngene international limited
8.2.10.1 Company Overview
8.2.10.2 Financial Performance
8.2.10.3 Product Benchmarking
8.2.10.4 Strategic Intiatives
8.2.10.5 Swot Analysis
8.2.11 Aurigene Discovery Technologies Limited
8.2.11.1 Company Overview
8.2.11.2 Financial Performance
8.2.11.3 Product Benchmarking
8.2.11.4 Strategic Initiatives
8.2.11.5 Swot Analysis
8.2.12 GVK Biosciences PVT. Ltd
8.2.12.1 Company Overview
8.2.12.2 Financial Performance
8.2.12.3 Product Benchmarking
8.2.12.4 Strategic Initiatives
8.2.12.5 Swot Analysis
List of Tables Table 1 List of secondary sources Table 2 List of Abbreviation
List of Figures Fig. 1 Market research process Fig. 2 Information procurement Fig. 3 Primary research pattern Fig. 4 Market research approaches Fig. 5 Value chain based sizing & forecasting Fig. 6 QFD modelling for market share assessment Fig. 7 Market formulation & validation Fig. 8 Indian clinical trials market summary Fig. 9 Indian clinical trials market segmentation Fig. 10 Market driver relevance analysis (Current & future impact) Fig. 11 Market restraint relevance analysis (Current & future impact) Fig. 12 Penetration & growth prospect mapping Fig. 13 SWOT analysis, by factor (political & legal, economic and technological) Fig. 14 Porter's five forces analysis Fig. 15 Phase wise clinical studies conducted in 2017 Fig. 16 Number of clinical trials conducted over the years in India Fig. 17 Clinical trial registration process flow Fig. 18 Indian clinical trials market phase outlook: Key takeaways Fig. 19 Indian clinical trials market: Phase movement analysis Fig. 20 Phase I market estimates and forecast, 2014 - 2025 (USD Million) Fig. 21 Phase II market estimates and forecast, 2014 - 2025 (USD Million) Fig. 22 Phase III market estimates and forecast, 2014 - 2025 (USD Million) Fig. 23 Phase IV market estimates and forecast, 2014 - 2025 (USD Million) Fig. 24 Indian clinical trials market study design outlook: Key takeaways Fig. 25 Indian clinical trials market: study design movement analysis Fig. 26 Interventional trials market estimates and forecast, 2014 - 2025 (USD Million) Fig. 27 Observational trials market estimates and forecast, 2014 - 2025 (USD Million) Fig. 28 Expanded access trials market estimates and forecast, 2014 - 2025 (USD Million) Fig. 29 Indian clinical trials market indication outlook: Key takeaways Fig. 30 Indian clinical trials market: indication movement analysis Fig. 31 Autoimmune/inflammation market estimates and forecast, 2014 - 2025 (USD Million) Fig. 32 Rheumatoid arthritis market estimates and forecast, 2014 - 2025 (USD Million) Fig. 33 Multiple sclerosis market estimates and forecast, 2014 - 2025 (USD Million) Fig. 34 Osteoarthritis market estimates and forecast, 2014 - 2025 (USD Million) Fig. 35 Irritable Bowel Syndrome (IBS) market estimates and forecast, 2014 - 2025 (USD Million) Fig. 36 Others market estimates and forecast, 2014 - 2025 (USD Million) Fig. 37 Pain management market estimates and forecast, 2014 - 2025 (USD Million) Fig. 38 Chronic pain market estimates and forecast, 2014 - 2025 (USD Million) Fig. 39 Acute pain market estimates and forecast, 2014 - 2025 (USD Million) Fig. 40 Oncology market estimates and forecast, 2014 - 2025 (USD Million) Fig. 41 Blood cancer market estimates and forecast, 2014 - 2025 (USD Million) Fig. 42 Solid tumors market estimates and forecast, 2014 - 2025 (USD Million) Fig. 43 Other market estimates and forecast, 2014 - 2025 (USD Million) Fig. 44 CNS Conditions market estimates and forecast, 2014 - 2025 (USD Million) Fig. 45 Epilepsy market estimates and forecast, 2014 - 2025 (USD Million) Fig. 46 Parkinson's Disease market estimates and forecast, 2014 - 2025 (USD Million) Fig. 47 Huntington's Disease market estimates and forecast, 2014 - 2025 (USD Million) Fig. 48 Stroke market estimates and forecast, 2014 - 2025 (USD Million) Fig. 49 Traumatic Brain Injury (TBI) market estimates and forecast, 2014 - 2025 (USD Million) Fig. 50 Amyotrophic Lateral Sclerosis (ALS) market estimates and forecast, 2014 - 2025 (USD Million) Fig. 51 Muscle regeneration market estimates and forecast, 2014 - 2025 (USD Million) Fig. 52 Others market estimates and forecast, 2014 - 2025 (USD Million) Fig. 53 Diabetes market estimates and forecast, 2014 - 2025 (USD Million) Fig. 54 Obesity market estimates and forecast, 2014 - 2025 (USD Million) Fig. 55 Cardiovascular market estimates and forecast, 2014 - 2025 (USD Million) Fig. 56 Others market estimates and forecast, 2014 - 2025 (USD Million) Fig. 57 Strategy framework
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
